Following the historic approval of Novo Nordisk's obesity drug Wegovy, stakeholders emphasize the need to identify appropriate patient populations and implement strategies for early disease detection and outcome monitoring. This marks a phase shift from regulatory clearance to effective large-scale clinical utilization of a promising metabolic therapy.